Thyrocare

Tests you can trust

July 23, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Sub: Press Release on Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Please find enclosed - the Press Release on the unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.

The same is also being made available on the Company's website https://investor.thyrocare.com/

We request you to please take the same on record.

Yours Faithfully,
For **Thyrocare Technologies Limited,**

Brijesh Kumar Digitally signed by Brijesh Kumar Date: 2026.07.23 15:57:51 +05'30'

Thyrocare Technologies Limited

Brijesh Kumar
Company Secretary and Compliance Officer

Encl. A/a

Thyrocare Technologies Limited
D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India 022- 3090 0000
enquiry@thyrocare.com www. thyrocare.com (CIN : L85110MH2000PLC123882)

Thyrocare
Tests you can trust

NEWS Release

Thyrocare Technologies Limited reports revenue of INR 240.02 Cr in Q1FY27 with a growth of 24% YoY

Revenue	EBITDA	PAT
⬆ **INR 240.02 Cr 24% YoY**	⬆ **INR 77.27 Cr 34% YoY**	⬆ **INR 51.33 Cr 34% YoY**

Navi Mumbai, July 23, 2026

Thyrocare Technologies Limited (hereinafter referred to as "**Thyrocare**" NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2027.

From Routine to Remarkable: The Next Frontier of Diagnostics

- **Thyrocare** expanded into **Specialty Diagnostics**, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with **Allergy** and **Genomics** and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times

Key Financial Highlights for Q1FY27

- **Consolidated revenue** registered a **24% year-on-year growth,** driven primarily by a **26%** increase in the **Pathology segment**
- In the **Pathology** business**, franchise** revenue grew by **27%** year-on-year**,** while **partnership** revenue recorded **26%** year-on-year growth
- Thyrocare, **India's largest diagnostic test volume processor**, processed **55.2 million tests** in **Q1FY27**, marking a strong **28%** year-on-year growth and reinforcing its volume leadership position in the industry
- **Consolidated EBITDA** grew by **34%** year-on-year to **Rs 77.27 Cr**, and **Profit After Tax (PAT)** grew by **34%** year-on-year to **Rs 51.33 Cr**
- **Sustained Six Sigma quality standards,** reducing complaints per million tests to **3.1 (down 24% YoY)** with **ATAT at 3.37 hours - India's first diagnostic chain** to hit this benchmark

Thyrocare Reports Robust Q1FY27 Results – Revenue Up 24%, PAT Up 34%

The company delivered a robust performance **in Q1FY27** with consolidated **revenue of ₹240.02 crore**, registering a strong **24% year-on-year growth**, led by continued momentum in the **Pathology** segment which grew **26% YoY**. **EBITDA** rose by **34% YoY** to ₹77.27 crore. **Profit After Tax** surged **34% YoY** to ₹51.33 crore, underscoring the company's focus on profitable growth.

India's largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing **55.2 million tests** up 28% year-on-year. The Pathology business maintained strong traction with **franchise revenue up 27%** and **partnership revenue up 26%** year-on-year.

Thyrocare's unwavering commitment to quality delivered **Six Sigma** excellence by reducing complaints to **3.1 per million** (down 24% YoY) with **ATAT** at **3.37 hours** from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark.

Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times

Senior management remarks:

"Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India"

– Rahul Guha, MD & CEO, Thyrocare Technologies Ltd

Consolidated Financial Performance for Q1FY27

Particulars	Quarter			Growth%	Annual
INR crore	**Q1FY27**	**Q4FY26**	**Q1FY26**	**YoY**	**FY26**
Revenue from operations	240.02	223.95	193.03	**24.3%**	829.04
Cost of materials consumed/sold	(62.16)	(56.68)	(55.63)		(219.57)
Gross margin	**177.86**	**167.27**	**137.40**	**29.4%**	**609.47**
Employee benefit expenses	(39.61)	(36.07)	(33.00)		(138.06)
Other expenses	(60.98)	(56.11)	(46.63)		(209.37)
EBITDA	**77.27**	**75.09**	**57.77**	**33.8%**	**262.04**
Depreciation and amortization	(12.49)	(14.03)	(11.41)		(58.58)
Finance cost	(1.35)	(1.52)	(0.78)		(2.80)
Other income	4.15	4.31	4.65		16.99
PBT and exceptional items	**67.58**	**63.85**	**50.23**	**34.5%**	**217.65**
Share of profit in associate entity	0.71	0.58	0.25		1.39
Exceptional items	0.00	0.00	0.00		(6.16)
Tax expenses	(16.96)	(15.73)	(12.19)		(50.03)
Profit after tax	**51.33**	**48.70**	**38.29**	**34.1%**	**162.85**
EPS	**3.23**	**3.06**	**2.41**	**34.0%**	**10.27**
Gross margin %	*74.1%*	*74.7%*	*71.2%*		*73.5%*
EBITDA%	*32.2%*	*33.5%*	*29.9%*		*31.6%*
PAT%	*21.4%*	*21.7%*	*19.8%*		*19.6%*

About Thyrocare

Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to patients, healthtech and wellness providers, insurance companies, pharmaceutical companies, franchisees, laboratories, hospitals and the government. Many leading healthcare product and services brands all over India use the comprehensive test profile menu offered by Thyrocare.

Thyrocare has an extensive network of laboratories across PAN India. Thyrocare has a Quarterly active franchise count of ~11,700 and processed 55.2mn diagnostic and screening investigations in Q1FY27.

Thyrocare is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations including ISO 9001-2000 rating as early as 2001, which was upgraded to ISO 9001:2015 and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations in 2005.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Both the companies assume no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Brijesh Kumar
Company Secretary and Compliance Officer
brijesh.jha@thyrocare.com

+91 84229 45537

Company: Thyrocare Technologies Limited
CIN: L85110MH2000PLC123882
Website: www.thyrocare.com